IP Library Granted Patent US 9,730,930
Granted Patent B2
US 9,730,930 · App. 14/715,322 · Granted Aug 15, 2017

Treatment for vitiligo

Inventor: Daniel Magilavy (San Francisco, CA)
Assignee: Rigel Pharmaceuticals, Inc.
A61K31/505A61K9/0014A61K9/0048A61K45/06A61K47/10C07D239/48A61K31/145A61K31/506
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,730,930
App. No.
14/715,322
Granted
Aug 15, 2017
Kind
B2
Abstract

Compounds I and II, as well as prodrugs, hydrates, solvates, N-oxides, salts and pharmaceutical compositions containing them, are useful for treating vitiligo. In certain embodiments, the compounds are provided in topical compositions.

Claims (15)

1. A method of treating vitiligo, comprising administering to a subject a topical formulation comprising from 0.1% to 10% (w/w) of a compound

or a hydrate, a solvate, an N-oxide, or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the subject is identified as having vitiligo.

3. The method of claim 1 , wherein the subject is identified as being at risk of developing vitiligo.

4. The method of claim 1 , wherein administering the topical formulation comprises administering a therapeutically effective amount of from about 0.0001 mg/kg/day to about 100 mg/kg/day.

5. The method of claim 1 , wherein the topical formulation comprises from 0.2% to 6% (w/w) of the compound.

6. The method of claim 1 , wherein the topical formulation comprises 3% (w/w) of the compound.

7. The method of claim 1 , wherein the topical formulation comprises 6% (w/w) of the compound.

8. The method of claim 5 , wherein the formulation comprises 30% to 40% (w/w) polyethylene glycol with an average molecular weight of from 4000 to 5000 Daltons.

9. The method of claim 1 , wherein the subject has one or more depigmented skin areas, and the method comprises administering the compound topically to at least one of the depigmented skin areas.

10. The method of claim 5 , further comprising administering the compound systemically to the subject.

11. The method of claim 1 , comprising administering the compound systemically to the subject.

12. The method of claim 1 , wherein the subject has vitiligo of the eye, and the compound ocularly to the patient.

13. The method of claim 1 , comprising administering the compound either in combination or adjunctively with a second therapeutic.

14. The method of claim 11 , wherein the second therapeutic is an anti-inflammatory, an antihistamine, an antibiotic, an antiviral medication, systemic phototherapy, psoralen photochemotherapy, excimer laser therapy, thyroid hormone replacement medication, or any combination thereof.

Assignments (2)
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2015
From: MAGILAVY, DANIEL
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 035667/0174 →
Continuity (3)
Continuation 14025609 · Sep 12, 2013
Provisional Application 61700153 · Sep 12, 2012
Related Publication 20150246039A1 · Sep 3, 2015